





Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H).		
313	 3-{{2-[[1-Cyano-1-(cyclopropylmethyl)-carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide  *159159*	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 0.21 (m, 2H); 0.40 (m, 2H); 1.02 (m, 1H); 1.69 (m, 4H); 2.57 (m, 2H); 3.03 (m, 2H); 4.22 (m, 2H); 7.38 (s, 1H); 7.70 (s, 2H); 7.90 (m, 1H); 8.16 (s, 1H); 8.49 (m, 1H); 9.40 (s, 1H); 10.51 (s, 1H).	MW: 607.775 MS (ESI) [M+1] ⁺ : 608	162 / 166





G00002


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
314	 4-{{2-[[1-Cyano-1-(2,2-difluoroethyl)carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethylpropionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.24 (m, 12H); 1.67 (m, 4H); 2.59 (m, 2H); 3.60 (m, 2H); 4.23 (m, 2H); 6.08 (tt, 1H); 7.08 (dd, 1H); 7.78 (d, 1H); 8.00 (m, 1H); 8.08 (s, 1H); 8.52 (d, 1H); 8.69 (m, 1H); 10.68 (s, 1H); 12.13 (s, 1H).	MW: 617.718 MS (ESI) [M+1] ⁺ : 618	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
315	 4-([2-[1-Cyano-1-ethylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino)-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.07 (m, 3H); 1.26 (m, 12H); 1.67 (m, 4H); 2.58 (m, 2H); 3.21 (m, 2H); 3.39 (m, 2H); 4.23 (m, 2H); 7.08 (dd, 1H); 7.77 (m, 2H); 8.04 (s, 1H); 8.53 (d, 1H); 8.65 (m, 1H); 10.58 (s, 1H); 12.13 (s, 1H).	MW: 581.738 MS (ESI) [M+1] ⁺ : 582	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
316	 4-{{[2-[1-Allylcarbamoyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 12H); 1.69 (m, 4H); 2.59 (m, 2H); 3.39 (m, 2H); 3.80 (m, 2H); 4.22 (m, 2H); 5.07 (dd, 1H); 5.12 (dd, 1H); 5.83 (m, 1H); 7.07 (dd, 1H); 7.77 (d, 1H); 7.88 (m, 1H); 8.06 (s, 1H); 8.52 (d, 1H); 8.68 (m, 1H); 10.58 (s, 1H); 12.12 (s,	MW: 593.749 MS (ESI) [M+1] ⁺ : 594	161 / 166



Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H).		
317	 4-{{[2-[1-Cyano-1-(cyanomethyl-carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26 (m, 12H); 1.69 (m, 4H); 2.59 (m, 2H); 3.38 (m, 2H); 4.15 (m, 2H); 4.22 (m, 2H); 7.10 (dd, 1H); 7.77 (d, 1H); 8.12 (s, 1H); 8.39 (m, 1H); 8.57 (d, 1H); 8.69 (m, 1H); 10.70 (s, 1H); 12.15 (s, 1H).	MW: 592.721 MS (ESI) [M+1] ⁺ : 593	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
318	 4-{{[2-[1-Cyano-1-(2-fluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.22 (m, 12H); 1.68 (m, 4H); 2.60 (m, 2H); 3.45 (m, 1H); 3.52 (m, 1H); 4.21 (m, 2H); 4.41 (m, 1H); 4.57 (m, 1H); 7.08 (dd, 1H); 7.77 (d, 1H); 7.83 (m, 1H); 8.08 (s, 1H); 8.55 (d, 1H); 8.67 (m, 1H); 10.60 (s, 1H); 12.16 (s, 1H).	MW: 599.728 MS (ESI) [M+1] ⁺ : 600	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
319	 4-{{[2-[1-Cyano-1-(cyclopropylmethyl)-carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 0.21 (m, 2H); 0.41 (m, 2H); 1.02 (m, 1H); 10.22 (m, 12H); 1.65 (m, 4H); 2.59 (m, 2H); 3.05 (m, 2H); 4.22 (m, 2H); 7.07 (dd, 1H); 7.77 (m, 2H); 8.04 (s, 1H); 8.56 (d, 1H); 8.68 (m, 1H); 10.58 (s, 1H); 12.11 (s, 1H).	MW: 607.775 MS (ESI) [M+1] ⁺ : 608	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
320	 3-{[2-[1-Cyano-1-prop-2-ynylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.23 (m, 12H); 1.68 (m, 4H); 2.57 (m, 2H); 3.08 (m, 1H); 3.92 (m, 2H); 4.26 (m, 2H); 7.41 (s, 1H); 7.71 (s, 1H); 7.93 (s, 1H); 8.15 (m, 2H); 8.52 (m, 1H); 9.42 (s, 1H); 10.58 (d, 1H).	MW: 591.733 MS (ESI) [M+1] ⁺ : 592	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
321	 3-({[2-[1-Cyano-1-ethylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.06 (m, 3H); 1.22 (m, 12H); 1.68 (m, 4H); 2.59 (m, 2H); 3.20 (m, 2H); 4.22 (m, 2H); 7.40 (s, 1H); 7.72 (m, 2H); 7.93 (s, 1H); 8.12 (m, 1H); 8.51 (m, 1H); 9.42 (s, 1H); 10.50 (d, 1H).	MW: 581.738 MS (ESI) [M+1] ⁺ : 582	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
322	 3-{[2-[1-Cyano-1-(2,2,2-trifluoroethylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethylpropionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.28 (m, 12H); 1.69 (m, 4H); 2.58 (m, 2H); 3.92 (m, 2H); 4.24 (m, 2H); 7.41 (s, 1H); 7.72 (s, 1H); 7.93 (s, 1H); 8.21 (m, 2H); 8.51 (m, 1H); 9.42 (s, 1H); 10.62 (s, 1H).	MW: 635.708 MS (ESI) [M+1] ⁺ : 636	162 / 166
323	 3-([2-[1-Cyano-1-(2-ethynylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino)-5-(2,2-dimethylpropionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ =	MW: 591.733 MS (ESI)	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	4- {[2-[1-Cyano-1-prop-2-ynylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	1.24 (m, 12H); 1.68 (m, 4H); 2.58 (m, 2H); 3.09 (m, 1H); 3.93 (m, 2H); 4.22 (m, 2H); 7.09 (dd, 1H); 7.78 (d, 1H); 8.12 (m, 2H); 8.53 (d, 1H); 8.68 (m, 1H); 10.62 (s, 1H); 12.12 (s, 1H).	[M+1] ⁺ : 592	
324	 3- {[2-[1-Cyano-1-(cyanomethyl-carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 12H); 1.70 (m, 4H); 2.60 (m, 2H); 4.15 (m, 2H);	MW: 592.721 MS (ESI) [M+1] ⁺ : 593	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	4.15 (m, 2H); 4.25 (m, 2H); 7.41 (s, 1H); 7.76 (s, 1H); 7.98 (s, 1H); 8.21 (s, 1H); 8.37 (s, 1H); 8.52 (m, 1H); 9.45 (s, 1H); 10.64 (s, 1H).		
325	 3-([2-[1-Allylcarbamoyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino)-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 12H); 1.70 (m, 4H); 2.58 (m, 2H); 3.80 (m, 2H); 4.25 (m, 2H); 5.08 (dd, 1H); 5.12 (dd, 1H);	MW: 593.749 MS (ESI) [M+1] ⁺ : 594	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		5.12 (dd, 1H); 5.83 (m, 1H); 7.41 (s, 1H); 7.71 (s, 1H); 7.88 (m, 1H); 7.98 (s, 1H); 8.52 (m, 1H); 9.42 (s, 1H); 10.51 (d, 1H).		
326	 4-{{[2-[1-Cyano-1-(2,2,2-trifluoroethyl)carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethylpropionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.22 (m, 12H); 1.68 (m, 4H); 2.61 (m, 2H); 3.40 (m, 2H); 3.95 (m, 2H); 4.23 (m, 2H); 7.09 (dd, 1H);	MW: 635.708 MS (ESI) [M+1] ⁺ : 636	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.77 (d, 1H); 8.11 (s, 1H); 8.25 (m, 1H); 8.56 (s, 1H); 8.67 (m, 1H); 10.67 (s, 1H); 12.12 (s, 1H).		
327	 5-([2-[1-Cyano-1-prop-2-ynylcarbamoylmeth-(Z or E)-ylidene]-3-ethyl-4-oxo-1,2,4-thiazolidin-5-ylidene]methyl)-2-diethylaminoethyl indole-3-carboxylic acid (2-diethylaminoethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 0.97 (m, 6H); 1.28 (m, 3H); 3.07 (s, 1H); 3.93 (m, 2H); 4.25 (m, 2H); 7.15 (dd, 1H); 7.41 (d, 1H); 7.86 (m, 1H); 8.05 (m, 4H); 10.52 (d, 1H); 11.59 (s,	MW: 533.654 MS (ESI) [M+1] ⁺ : 534	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H).		
328	 5-({[2-[1-Cyano-1-(cyclopropylmethyl)-carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ , 300 MHz) δ = 0.26 (m, 2H); 0.57 (m, 2H); 1.10 (m, 7H); 1.41 (m, 3H); 2.62 (m, 4H); 2.72 (m, 2H); 3.22 (m, 2H); 3.55 (m, 2H); 4.40 (m, 2H); 6.29 (m, 1H); 6.90 (m, 1H); 6.98 (dd, 1H); 7.40 (d, 1H); 7.68 (d, 1H); 7.80 (s, 1H); 7.90 (d, 1H); 8.90 (s,	MW: 549.696 MS (ESI) [M+1] ⁺ : 550	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H); 10.66 (d, 1H).		
329	 5-{[2-[1-Allylcarbamoyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ , 300 MHz) (selected peaks) δ = 1.10 (m, 6H); 1.42 (m, 3H); 2.66 (m, 4H); 2.75 (m, 2H); 3.56 (m, 2H); 4.0 (m, 2H); 4.40 (m, 2H); 5.19 (dd, 1H); 5.26 (dd, 1H); 5.90 (m, 1H); 6.28 (m, 1H); 6.90 (s, 1H); 6.98 (dd, 1H); 7.40 (d, 1H); 7.65 (m,	MW: 535.67 MS (ESI) [M+1] ⁺ : 536	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H); 7.77 (s, 1H); 7.88 (m, 1H); 9.17 (s, 1H); 10.65 (s, 1H).		
330	 5-{[2-[1-Cyano-1-(2,2,2-trifluoroethyl)carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ , 300 MHz) (selected peaks) δ = 1.0 (m, 6H); 1.29 (m, 3H); 3.97 (m, 2H); 4.25 (m, 2H); 7.13 (dd, 1H); 7.42 (d, 1H); 7.85 (m, 1H); 8.01 (dd, 1H); 8.16 (m, 1H); 10.58 (s, 1H); 11.59 (d, 1H).	MW: 577.629 MS (ESI) [M+1] ⁺ : 578	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
331	 5-{{[2-[[1-cyano-1-propylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ + DMSO-d ₆ , 300 MHz) δ = 0.88 (m, 3H); 1.01 (m, 6H); 1.35 (m, 3H); 1.52 (m, 2H); 2.52 (m, 4H); 2.60 (m, 2H); 3.25 (m, 2H); 3.48 (m, 2H); 4.31 (m, 2H); 6.12 (m, 1H); 6.75 (s, 1H); 6.88 (dd, 1H); 7.31 (d, 1H); 7.61 (d, 1H); 7.68 (s, 1H); 7.80 (d, 1H); 10.08 (s, 1H); 10.60 (d,	MW: 537.685 MS (ESI) [M+1] ⁺ : 538	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H).		
332	 5-{[2-[1-Cyano-1-isopropylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ and DMSO-d ₆ , 300 MHz) δ = 1.06 (m, 6H); 1.18 (m, 6H); 1.36 (m, 3H); 2.57 (m, 4H); 2.69 (m, 2H); 3.50 (m, 2H); 4.10 (m, 1H); 4.31 (m, 2H); 5.92 (m, 1H); 6.81 (s, 1H); 6.90 (dd, 1H); 7.35 (d, 1H); 7.72 (s, 1H); 7.88 (d, 1H); 10.42 (s, 1H); 10.61 (d, 1H).	MW: 537.685 MS (ESI) [M+1] ⁺ : 538	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
333	 6-{{2-[[1-cyano-1-(cyanomethyl-carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26 (m, 3H); 2.20 (s, 6H); 2.38 (m, 2H); 4.14 (d, 2H); 4.22 (m, 2H); 7.11 (d, 1H); 7.30 (s, 1H); 7.80 (m, 1H); 7.97 (d, 1H); 8.08 (d, 1H); 8.18 (s, 1H); 8.30 (m, 1H); 10.50 (s, 1H); 11.49 (s, 1H).	MW: 506.588 MS (ESI) [M+1] ⁺ : 507	160 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
334	 6-{{2-[[1-Cyano-1-prop-2-ynylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 3H); 2.20 (s, 6H); 2.39 (m, 2H); 2.90 (m, 2H); 3.08 (m, 1H); 3.92 (m, 2H); 4.25 (m, 2H); 7.10 (dd, 1H); 7.30 (s, 1H); 7.80 (m, 1H); 7.95 (d, 1H); 8.05 (m, 2H); 8.13 (s, 1H); 10.40 (s, broad, 1H); 11.48 (s, 1H).	MW: 505.600 MS (ESI) [M+1] ⁺ : 506	160 / 166



Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
335	 6-{{2-[[1-cyano-1-(cyclopropylmethyl)-carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 0.22 (m, 2H); 0.40 (m, 2H); 1.02 (m, 1H); 1.25 (m, 3H); 2.20 (s, 6H); 2.39 (m, 2H); 3.03 (m, 2H); 4.22 (m, 2H); 7.11 (d, 1H); 7.30 (s, 1H); 7.71 (m, 1H); 7.80 (m, 1H); 7.97 (d, 1H); 8.09 (m, 2H); 10.48 (s, 1H); 11.48 (s, 1H).	MW: 521.642 MS (ESI) [M+1] ⁺ : 522	160 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
336	 6-{{2-[[1-Cyano-1-(2,2-difluoroethyl)carbonyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.23 (m, 3H); 2.18 (s, 6H); 2.39 (m, 2H); 3.60 (m, 2H); 4.25 (m, 2H); 6.08 (tt, 1H); 7.11 (dd, 1H); 7.31 (s, 1H); 7.80 (m, 1H); 7.95 (m, 2H); 8.09 (d, 1H); 8.12 (s, 1H); 10.48 (s, 1H); 11.48 (s, 1H).	MW: 531.585 MS (ESI) [M+1] ⁺ : 532	160/ 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
337	 6-{{[2-[[1-Cyano-1-(2-fluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}]-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 3H); 2.19 (s, 6H); 2.40 (m, 2H); 3.50 (dq, 2H); 4.25 (m, 2H); 4.40 (m, 1H); 4.58 (m, 1H); 7.10 (dd, 1H); 7.30 (s, 1H); 7.79 (m, 1H); 7.95 (d, 1H); 8.05 (d, 1H); 8.12 (s, 1H); 10.41 (s, 1H); 11.49 (s, 1H).	MW: 513.595 MS (ESI) [M+1] ⁺ : 514	160 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
338	 6-{{[2-[1-Allylcarbamoyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 3H); 2.18 (s, 6H); 2.39 (m, 2H); 3.80 (m, 2H); 4.25 (m, 2H); 5.08 (dd, 1H); 5.12 (dd, 1H); 5.81 (m, 1H); 7.10 (dd, 1H); 7.30 (s, 1H); 7.80 (m, 1H); 7.95 (d, 1H); 8.08 (d, 1H); 8.10 (s, 1H); 10.38 (s, 1H); 11.48 (s, 1H).	MW: 507.616 MS (ESI) [M+1] ⁺ : 508	160 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
339	 6-{[2-[1-Cyano-1-ethylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.05 (m, 3H); 1.25 (m, 3H); 2.20 (s, 6H); 2.40 (m, 2H); 3.20 (m, 2H); 4.22 (m, 2H); 7.11 (dd, 1H); 7.30 (s, 1H); 7.67 (m, 1H); 7.80 (m, 1H); 7.93 (d, 1H); 8.06 (d, 1H); 8.12 (s, 1H); 10.48 (d, 1H); 11.48 (s, 1H).	MW: 495.605 MS (ESI) [M+1] ⁺ : 496	160 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
340	 6-([2-([1-Cyano-1-(2,2,2-trifluoroethyl)carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino)-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 3H); 2.19 (s, 6H); 2.40 (m, 2H); 3.96 (m, 2H); 4.25 (m, 2H); 7.12 (dd, 1H); 7.33 (s, 1H); 7.80 (m, 1H); 7.97 (d, 1H); 8.08 (d, 1H); 8.16 (m, 2H); 10.49 (s, 1H); 11.49 (s, 1H).	MW: 549.575 MS (ESI) [M+1] ⁺ : 550	160 / 166
341		¹ H-NMR (DMSO-d ₆ , 300 MHz) δ =	MW: 563.602	158 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	5- {[2-[1-Cyano-1-(2,2,2-trifluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	1.25 (m, 3H); 2.18 (s, 6H); 2.48 (m, 2H); 3.11 (s, 3H); 3.60 (m, 2H); 3.95 (m, 2H); 4.26 (m, 2H); 7.14 (dd, 1H); 7.41 (d, 1H); 7.70 (s, 1H); 7.78 (d, 1H); 8.12 (m, 2H); 10.50 (s, 1H); 11.60 (s, 1H).	MS (ESI) [M+1] ⁺ : 564	
342	 5- {[2-[1-Cyano-1-(2,2-difluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.24 (m, 3H); 2.18 (s, 6H); 2.48 (m, 2H); 3.12 (s, 3H); 3.57	MW: 545.612 MS (ESI) [M+1] ⁺ : 546	158/ 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethyl-4-oxo-thiazolidin-(5E/Z)-ylidene-methyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	3.12 (s, 3H); 3.57 (m, 4H); 4.22 (m, 2H); 6.08 (tt, 1H); 7.11 (dd, 1H); 7.40 (d, 1H); 7.61 (s, 1H); 7.71 (s, 1H); 7.79 (m, 1H); 8.11 (s, 1H); 10.0 (s, broad, 1H); 11.58 (s, 1H).		
343	 5-{[2-[1-Cyano-1-ethylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.07 (m, 3H); 1.29 (m, 3H); 2.18 (s, 6H); 2.45 (m, 2H); 3.11 (s, 3H);	MW: 509.631 MS (ESI) [M+1] ⁺ : 510	158 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	methyl-amide	3.21 (m, 2H); 3.60 (m, 2H); 4.22 (m, 2H); 7.15 (dd, 1H); 7.42 (d, 1H); 7.62 (m, 1H); 7.69 (s, 1H); 7.75 (d, 1H); 8.05 (d, 1H); 10.40 (d, 1H); 11.60 (d, 1H).		
344	 5-{{[2-[1-Allylcarbamoyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.25 (m, 3H); 2.17 (s, 6H); 2.42 (m, 2H); 3.11 (s, 3H); 3.58 (m, 2H); 3.79 (m, 2H); 4.26 (m, 2H);	MW: 521.642 MS (ESI) [M+1] ⁺ : 522	158/ 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		4.26 (m, 2H); 5.06 (dd, 1H); 5.12 (dd, 1H); 5.88 (m, 1H); 7.13 (dd, 1H); 7.41 (d, 1H); 7.69 (s, 1H); 7.73 (d, 1H); 7.80 (m, 1H); 8.06 (s, 1H); 10.39 (s, 1H); 11.60 (s, 1H).		
345	 5-{[2-[1-Cyano-1-(2-fluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26 (m, 3H); 2.18 (s, 6H); 3.11 (s, 3H); 3.49 (dd, 2H); 3.60 (m, 2H);	MW: 527.622 MS (ESI) [M+1] ⁺ : 528	158 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethyl)-methyl-amide	3.60 (m, 2H); 4.24 (m, 2H); 4.50 (dt, 2H); 7.18 (dd, 1H); 7.41 (d, 1H); 7.69 (s, 1H); 7.77 (d, 1H); 8.08 (d, 1H); 10.47 (d, 1H); 11.60 (s, 1H).		
346	 5-{{[2-[1-Cyano-1-(cyclopropylmethyl)-carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 0.21 (m, 2H); 0.40 (m, 2H); 1.02 (m, 1H); 1.25 (m, 3H); 2.16 (s, 6H); 2.48 (m, 2H); 3.07 (m, 2H);	MW: 535.669 MS (ESI) [M+1] ⁺ : 536	158 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		3.10 (s, 3H); 3.60 (m, 2H); 4.27 (m, 2H); 7.12 (dd, 1H); 7.42 (d, 1H); 7.70 (s, 1H); 7.78 (d, 1H); 8.05 (s, 1H); 10.40 (s, 1H); 11.60 (s, 1H).		
347	 5-{{[2-[1-Cyano-1-prop-2-ynylcarbamoylmeth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.22 (m, 3H); 2.15 (s, 6H); 2.47 (m, 2H); 3.08 (m, 1H); 3.12 (s, 3H); 3.58 (m, 2H); 3.92 (m, 2H);	MW: 519.627 MS (ESI) [M+1] ⁺ : 520	158 / 166



Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		4.22 (m, 2H); 7.11 (dd, 1H); 7.41 (d, 1H); 7.69 (s, 1H); 7.75 (s, 1H); 8.0 (s, 1H); 8.08 (s, 1H); 10.40 (s, broad, 1H); 11.58 (s, 1H).		
348	 5-[[2-[1-Cyano-2-morpholin-4-yl-2-oxo-ethylidene]-3-ethyl-4-oxo-thiazolidin-5E/Z-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ , 300 MHz) δ = 1.09 (m, 6H); 1.42 (m, 3H); 2.68 (m, 4H); 2.75 (m, 3H); 3.59 (m, 2H); 3.70 (m, 4H); 7.76 (m, 4H); 4.40 (m, 2H);	MW: 565.695 MS (ESI) [M+1] ⁺ : 566	159 / 166

Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		6.94 (m, 2H); 7.48 (d, 1H); 7.61 (d, 1H); 7.78 (s, 1H); 7.88 (d, 1H); 9.32 (s, 1H); 10.63 (d, 1H).		
349	 2-Cyano-2-[5-[1-{4-[(2-dimethylamino-ethyl)-methyl-sulfamoyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-prop-2-ynyl-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.28 (m, 3H); 2.12 (s, 6H); 2.40 (m, 2H); 2.69 (s, 3H); 3.02 (m, 2H); 3.09 (m, 1H); 3.93 (m, 2H); 4.24 (m, 2H); 7.50 (d, 2H);	MW: 516.644 MS (ESI) [M+1] ⁺ : 517	156 / 166



Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.71 (d, 2H); 8.19 (s, 1H); 10.58 (s, 1H).		
350	 2-Cyano-2-[5-[1-{3-[(2-dimethylamino-ethyl)-methyl-sulfamoyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-prop-2-ynyl-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.24 (m, 3H); 2.19 (s, 6H); 2.42 (m, 2H); 2.72 (s, 3H); 3.08 (m, 2H); 3.92 (m, 2H); 4.23 (m, 2H); 7.42 (d, 1H); 7.60 (m, 1H); 7.68 (m, 2H); 8.19 (m, 2H); 10.50 (s, 1H).	MW: 516.644 MS (ESI) [M+1] ⁺ : 517	164 / 166




Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
351	 2-Cyano-2-[5-[1-[3-(2-dimethylamino-ethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-prop-2-ynyl-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.24 (m, 3H); 2.06 (s, 6H); 2.27 (m, 2H); 2.82 (m, 2H); 2.91 (s, 3H); 3.08 (m, 1H); 3.92 (m, 2H); 4.22 (m, 2H); 7.44 (m, 1H); 7.54 (m, 2H); 7.71 (s, 1H); 8.16 (m, 2H); 10.55 (s, 1H).	MW: 502.617 MS (ESI) [M+1] ⁺ : 503	165 / 166




Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
352	 N-Allyl-2-cyano-2-[5-[1-[4-(2-dimethylaminoethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.28 (m, 3H); 2.08 (s, 6H); 2.25 (m, 2H); 2.80 (m, 2H); 3.80 (m, 2H); 4.22 (m, 2H); 5.05 (dd, 1H); 5.13 (dd, 1H); 5.82 (m, 1H); 7.41 (s, 1H); 7.46 (d, 2H); 7.73 (d, 2H); 7.92 (m, 1H); 8.17 (m, 1H); 10.50 (d, 1H).	MW: 504.633 MS (ESI) [M+1] ⁺ : 505	163 / 166




Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
353	 2-Cyano-2-[5-[1-[4-(2-dimethylamino)-ethylsulfamoyl]-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-(2,2,2-trifluoroethyl)-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.28 (m, 3H); 2.07 (s, 6H); 2.25 (m, 2H); 2.80 (m, 2H); 3.96 (m, 2H); 4.25 (m, 2H); 7.41 (s, 1H); 7.48 (d, 2H); 7.73 (d, 2H); 8.20 (s, 1H); 8.29 (m, 1H); 10.59 (s, 1H).	MW: 546.592 MS (ESI) [M+1] ⁺ : 547	163 / 166
354		¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26	MW: 502.617 MS (ESI)	163 / 166




Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	2-Cyano-2-[5-[1-[4-(2-dimethylamino-ethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-prop-2-ynyl-acetamide	(m, 3H); 2.08 (s, 6H); 2.28 (m, 2H); 2.80 (m, 2H); 3.08 (m, 1H); 3.93 (m, 2H); 4.22 (m, 2H); 7.41 (s, 1H); 7.47 (d, 2H); 7.72 (d, 2H); 8.18 (m, 2H); 10.52 (s, 1H).	[M+1] ⁺ : 503	




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
355		MW: 612.70 MS (ESI) [M+1] ⁺ : 613	149 / 166
356		MW: 586.60 MS (ESI) [M+1] ⁺ : 587	149 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
357		MW: 532.66 MS (ESI) [M+1] ⁺ : 533	149 / 166
358	 6-{{2-[1-Cyano-1-prop-2-ynylcarbamoylmeth-(E or Z)-ylidene]-3-ethyl-4-oxothiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-naphthalene-2-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide	MW: 542.66 MS (ESI) [M+1] ⁺ : 543	149 / 166
359		MW: 595.72 MS (ESI) [M+1] ⁺ : 596	149 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
363		MW: 574.70 MS (ESI) [M+1] ⁺ : 575	146 / 166
364		MW: 539.66 MS (ESI) [M+1] ⁺ : 540	146 / 166
365	 N-tert-Butyl-2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin[2-(E or Z)]-ylidene]-N-methylacetamide	MW: 524.69 MS (ESI) [M+1] ⁺ : 525	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
366		MW: 581.74 MS (ESI) [M+1] ⁺ : 582	146 / 166
367		MW: 507.62 MS (ESI) [M+1] ⁺ : 508	146 / 166
368		MW: 540.69 MS (ESI) [M+1] ⁺ : 541	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
369		MW: 508.64 MS (ESI) $[M+1]^+$: 509	146 / 166
370		MW: 536.70 MS (ESI) $[M+1]^+$: 537	146 / 166
371		MW: 510.66 MS (ESI) $[M+1]^+$: 511	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
372		MW: 562.67 MS (ESI) [M+1] ⁺ : 563	146 / 166
373		MW: 574.70 MS (ESI) [M+1] ⁺ : 575	146 / 166
374		MW: 536.58 MS (ESI) [M+1] ⁺ : 537	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
375		MW: 494.62 MS (ESI) [M+1] ⁺ : 495	146 / 166
376	 2-Cyano-N-cyclopropylmethyl-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl)propionylamino)-phenylamino]-methylidene]-thiazolidin-2-ylidene]-acetamide	MW: 508.64 MS (ESI) [M+1] ⁺ : 5098	146 / 166
377		MW: 576.69 MS (ESI) [M+1] ⁺ : 577	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
381		MW: 570.70 MS (ESI) [M+1] ⁺ : 575	146 / 166
382	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-N-(2-pyridin-2-yl-ethyl)-acetamide	MW: 559.69 MS (ESI) [M+1] ⁺ : 560	146 / 166
383		MW: 545.67 MS (ESI) [M+1] ⁺ : 546	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
384		MW: 526.66 MS (ESI) $[M+1]^+$: 527	146 / 166
385		MW: 524.69 MS (ESI) $[M+1]^+$: 525	146 / 166
386		MW: 574.70 MS (ESI) $[M+1]^+$: 575	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
387		MW: 528.70 MS (ESI) $[M+1]^+$: 529	146 / 166
388		MW: 579.77 MS (ESI) $[M+1]^+$: 580	146 / 166
389		MW: 551.71 MS (ESI) $[M+1]^+$: 552	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
393		MW: 524.69 MS (ESI) [M+1] ⁺ : 525	146 / 166
394	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin- [2-(E or Z)]-ylidene]-N-phenyl-acetamide	MW: 530.65 MS (ESI) [M+1] ⁺ : 531	146 / 166
395		MW: 534.68 MS (ESI) [M+1] ⁺ : 535	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
396		MW: 539.70 MS (ESI) $[M+1]^+$: 540	146 / 166
397		MW: 540.69 MS (ESI) $[M+1]^+$: 541	146 / 166
398		MW: 572.73 MS (ESI) $[M+1]^+$: 573	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
399		MW: 572.73 MS (ESI) $[M+1]^+$: 573	146 / 166
400		MW: 575.73 MS (ESI) $[M+1]^+$: 576	146 / 166
401	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-2-(E or Z)-ylidene]-N-[2-(4-fluoro-phenyl)-ethyl]-acetamide	MW: 576.69 MS (ESI) $[M+1]^+$: 577	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
405		MW: 557.67 MS (ESI) [M+1] ⁺ : 558	145 / 166
406		MW: 589.72 MS (ESI) [M+1] ⁺ : 590	145 / 166
407		MW: 555.70 MS (ESI) [M+1] ⁺ : 556	145 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
408	 1-(4-{{2-[1-Cyano-2-(3-hydroxy-pyrrolidin-1-yl)-2-oxo-eth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-3-(2-pyrrolidin-1-yl-ethyl)-urea	MW: 539.66 MS (ESI) [M+1] ⁺ : 540	145 / 166
409		MW: 554.67 MS (ESI) [M+1] ⁺ : 555	145 / 166
410		MW: 596.75 MS (ESI) [M+1] ⁺ : 597	145 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
411		MW: 522.63 MS (ESI) $[M+1]^+$: 523	145 / 166
412	 2-Cyano-N-cyclohexyl-2-[3-ethyl-4-oxo-5-[1-{4-[3-(2-pyrrolidin-1-yl-ethyl)-ureido]-phenylamino}-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-acetamide	MW: 551.71 MS (ESI) $[M+1]^+$: 552	145 / 166
413		MW: 525.67 MS (ESI) $[M+1]^+$: 526	145 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
417		MW: 591.71 MS (ESI) $[M+1]^+$: 592	145 / 166
418		MW: 507.62 MS (ESI) $[M+1]^+$: 508	145 / 166
419		MW: 589.68 MS (ESI) $[M+1]^+$: 590	145 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
422		MW: 574.71 MS (ESI) [M+1] ⁺ : 575	145 / 166
423		MW: 560.68 MS (ESI) [M+1] ⁺ : 561	145 / 166
424		MW: 541.67 MS (ESI) [M+1] ⁺ : 542	145 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
425		MW: 539.70 MS (ESI) [M+1] ⁺ : 540	145 / 166
426		MW: 589.72 MS (ESI) [M+1] ⁺ : 590	145 / 166
427		MW: 582.77 MS (ESI) [M+1] ⁺ : 583	145 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
428		MW: 543.71 MS (ESI) $[M+1]^+$: 544	145 / 166
429		MW: 566.73 MS (ESI) $[M+1]^+$: 567	145 / 166
430		MW: 555.70 MS (ESI) $[M+1]^+$: 556	145 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
431		MW: 539.70 MS (ESI) $[M+1]^+$: 540	145 / 166
432		MW: 539.70 MS (ESI) $[M+1]^+$: 540	145 / 166
433		MW: 542.66 MS (ESI) $[M+1]^+$: 543	145 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
434		MW: 574.70 MS (ESI) [M+1] ⁺ : 575	147 / 166
435	 4-{[2-[1-Cyano-1-[(2-hydroxy-ethyl)-propyl-carbamoyl]-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 540.69 MS (ESI) [M+1] ⁺ : 541	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
436		MW: 524.64 MS (ESI) $[M+1]^+$: 525	147 / 166
437		MW: 508.64 MS (ESI) $[M+1]^+$: 509	147 / 166
438		MW: 556.71 MS (ESI) $[M+1]^+$: 557	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
439		MW: 581.74 MS (ESI) [M+1] ⁺ : 582	147 / 166
440		MW: 507.62 MS (ESI) [M+1] ⁺ : 508	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI)	Educt/ Synthe- sis as in the Case of
441	 4-{{2-[[1-Cyano-1-[[ethyl-(2-methoxyethyl)-carbamoyl]-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidene-methyl]-amino}]-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 540.69 MS (ESI) [M+1] ⁺ : 541	147 / 166
442		MW: 536.70 MS (ESI) [M+1] ⁺ : 537	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
443		MW: 510.66 MS (ESI) [M+1] ⁺ : 511	147 / 166
444		MW: 562.67 MS (ESI) [M+1] ⁺ : 563	147 / 166
445		MW: 574.70 MS (ESI) [M+1] ⁺ : 575	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
446	 4-{[2-[1-Cyano-1-(2,2,2-trifluoroethylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 536.58 MS (ESI) [M+1] ⁺ : 537	147 / 166
447		MW: 492.60 MS (ESI) [M+1] ⁺ : 493	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
448		MW: 508.64 MS (ESI) [M+1] ⁺ : 509	147 / 166
449		MW: 574.70 MS (ESI) [M+1] ⁺ : 575	147 / 166
450		MW: 559.69 MS (ESI) [M+1] ⁺ : 560	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
451		MW: 545.67 MS (ESI) [M+1] ⁺ : 546	147 / 166
452		MW: 526.66 MS (ESI) [M+1] ⁺ : 527	147 / 166
453		MW: 524.69 MS (ESI) [M+1] ⁺ : 525	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
454		MW: 574.70 MS (ESI) [M+1] ⁺ : 575	147 / 166
455		MW: 567.76 MS (ESI) [M+1] ⁺ : 568	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
456	 4-{{[2-[1-Cyano-1-(2-methylsulfonyl-ethylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 528.70 MS (ESI) [M+1] ⁺ : 529	147 / 166
457		MW: 579.77 MS (ESI) [M+1] ⁺ : 580	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
458		MW: 551.71 MS (ESI) $[M+1]^+$: 552	147 / 166
459		MW: 540.69 MS (ESI) $[M+1]^+$: 541	147 / 166
460		MW: 540.69 MS (ESI) $[M+1]^+$: 541	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
461	 4-{{2-[1-Cyano-1-(pyrrol-1-ylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 519.63 MS (ESI) [M+1] ⁺ : 520	147 / 166
462		MW: 548.71 MS (ESI) [M+1] ⁺ : 549	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
463		MW: 530.65 MS (ESI) [M+1] ⁺ : 531	147 / 166
464		MW: 539.70 MS (ESI) [M+1] ⁺ : 540	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
465	 4-{[2-[1-Cyano-1-(2-dimethylamino-1-methyl-ethylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 539.70 MS (ESI) [M+1] ⁺ : 540	147 / 166
466		MW: 572.73 MS (ESI) [M+1] ⁺ : 573	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
467		MW: 572.73 MS (ESI) $[M+1]^+$: 573	147 / 166
468		MW: 573.68 MS (ESI) $[M+1]^+$: 574	147 / 166
469		MW: 571.70 MS (ESI) $[M+1]^+$: 572	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
470		MW: 603.74 MS (ESI) [M+1] ⁺ : 604	143/166
471		MW: 553.69 MS (ESI) [M+1] ⁺ : 554	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
472	 N-(2-Acetylamino-ethyl)-2-cyano-2-[3-ethyl-5-[1-{4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-[2-(E or Z)]-ylidene]-acetamide	MW: 568.70 MS (ESI) [M+1] ⁺ : 569	143/166
473		MW: 537.69 MS (ESI) [M+1] ⁺ : 538	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
474		MW: 585.76 MS (ESI) $[M+1]^+$: 586	143/166
475		MW: 565.74 MS (ESI) $[M+1]^+$: 566	143/166
476		MW: 539.70 MS (ESI) $[M+1]^+$: 540	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
477		MW: 591.71 MS (ESI) $[M+1]^+$: 592	143/166
478		MW: 603.74 MS (ESI) $[M+1]^+$: 604	143/166
479		MW: 565.62 MS (ESI) $[M+1]^+$: 566	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
480		MW: 511.65 MS (ESI) $[M+1]^+$: 512	143/166
481		MW: 523.66 MS (ESI) $[M+1]^+$: 524	143/166
482		MW: 537.69 MS (ESI) $[M+1]^+$: 538	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
483		MW: 605.74 MS (ESI) [M+1] ⁺ : 606	143/166
484	 2-Cyano-2-[3-ethyl-5-[1-{4-[3-(4-methylpiperazin-1-yl)-propionylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N-prop-2-ynyl-acetamide	MW: 521.64 MS (ESI) [M+1] ⁺ : 522	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
485		MW: 541.67 MS (ESI) $[M+1]^+$: 542	143/166
486		MW: 537.69 MS (ESI) $[M+1]^+$: 538	143/166
487		MW: 603.74 MS (ESI) $[M+1]^+$: 604	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
488		MW: 588.73 MS (ESI) $[M+1]^+$: 589	143/166
489		MW: 574.71 MS (ESI) $[M+1]^+$: 575	143/166
490		MW: 555.70 MS (ESI) $[M+1]^+$: 556	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
491		MW: 553.73 MS (ESI) [M+1] ⁺ : 554	143/166
492		MW: 603.74 MS (ESI) [M+1] ⁺ : 604	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
493	 2-Cyano-2-[3-ethyl-5-[1-{4-[3-(4-methylpiperazin-1-yl)-propionylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-[2-(E or Z)]-ylidene]-N-(2-methylsulfanyl-ethyl)-acetamide	MW: 557.74 MS (ESI) [M+1] ⁺ : 558	143/166
494		MW: 608.81 MS (ESI) [M+1] ⁺ : 609	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
495		MW: 580.75 MS (ESI) $[M+1]^+$: 581	143/166
496		MW: 569.73 MS (ESI) $[M+1]^+$: 570	143/166
497		MW: 569.73 MS (ESI) $[M+1]^+$: 570	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
498		MW: 548.67 MS (ESI) [M+1] ⁺ : 549	143/166
499		MW: 525.67 MS (ESI) [M+1] ⁺ : 526	143/166
500		MW: 539.70 MS (ESI) [M+1] ⁺ : 540	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
501		MW: 541.67 MS (ESI) [M+1] ⁺ : 542	143/166
502		MW: 541.67 MS (ESI) [M+1] ⁺ : 542	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
503	 2-Cyano-N-(1,1-diethyl-prop-2-ynyl)-2-[3-ethyl-5-[1-{4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-[2-(E or Z)]-ylidene]-acetamide	MW: 577.75 MS (ESI) [M+1] ⁺ : 578	143/166
504		MW: 553.73 MS (ESI) [M+1] ⁺ : 554	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
505		MW: 553.73 MS (ESI) $[M+1]^+$: 554	143/166
506		MW: 553.73 MS (ESI) $[M+1]^+$: 554	143/166
507		MW: 559.69 MS (ESI) $[M+1]^+$: 560	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
508		MW: 569.73 MS (ESI) [M+1] ⁺ : 570	143/166
509		MW: 601.77 MS (ESI) [M+1] ⁺ : 602	143/166
510		MW: 601.77 MS (ESI) [M+1] ⁺ : 602	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
511		MW: 604.78 MS (ESI) [M+1] ⁺ : 605	143/166
512		MW: 589.76 MS (ESI) [M+1] ⁺ : 590	143/166
513		MW: 613.78 MS (ESI) [M+1] ⁺ : 614	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
514		MW: 615.80 MS (ESI) [M+1] ⁺ : 616	143/166
515	 2-Cyano-N-(2,3-dihydroxy-propyl)-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-N-methyl-acetamide	MW: 499.63 MS (ESI) [M+1] ⁺ : 500	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
516		MW: 531.68 MS (ESI) [M+1] ⁺ : 532	142/166
517		MW: 497.66 MS (ESI) [M+1] ⁺ : 498	142/166
518		MW: 481.62 MS (ESI) [M+1] ⁺ : 482	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
519		MW: 496.63 MS (ESI) $[M+1]^+$: 497	142/166
520		MW: 464.59 MS (ESI) $[M+1]^+$: 465	142/166
521		MW: 497.66 MS (ESI) $[M+1]^+$: 498	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
522		MW: 493.67 MS (ESI) [M+1] ⁺ : 494	142/166
523		MW: 523.61 MS (ESI) [M+1] ⁺ : 524	142/166
524		MW: 467.64 MS (ESI) [M+1] ⁺ : 468	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
525		MW: 519.64 MS (ESI) $[M+1]^+$: 520	142/166
526		MW: 531.68 MS (ESI) $[M+1]^+$: 532	142/166
527		MW: 493.55 MS (ESI) $[M+1]^+$: 494	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
528		MW: 533.67 MS (ESI) [M+1] ⁺ : 534	142/166
529		MW: 449.58 MS (ESI) [M+1] ⁺ : 450	142/166
530		MW: 531.64 MS (ESI) [M+1] ⁺ : 532	142/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
531		MW: 513.69 MS (ESI) [M+1] ⁺ : 514	142/166
532	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-N-(2-methyl-allyl)-acetamide	MW: 465.62 MS (ESI) [M+1] ⁺ : 466	142/166
533		MW: 483.63 MS (ESI) [M+1] ⁺ : 484	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
534		MW: 481.66 MS (ESI) [M+1] ⁺ : 482	142/166
535		MW: 531.68 MS (ESI) [M+1] ⁺ : 532	142/166
536		MW: 497.66 MS (ESI) [M+1] ⁺ : 498	142/166

Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
537		MW: 476.60 MS (ESI) $[M+1]^+$: 477	142/166
538		MW: 517.65 MS (ESI) $[M+1]^+$: 518	142/166
539		MW: 469.61 MS (ESI) $[M+1]^+$: 470	142/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
540	 2-Cyano-N-(cyano-dimethyl-methyl)-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-acetamide	MW: 478.62 MS (ESI) [M+1] ⁺ : 479	142/166
541		MW: 505.68 MS (ESI) [M+1] ⁺ : 506	142/166
542		MW: 481.66 MS (ESI) [M+1] ⁺ : 482	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI)	Educt/ Synthe- sis as in the Case of
543		MW: 481.66 MS (ESI) [M+1] ⁺ : 482	142/166
544		MW: 487.63 MS (ESI) [M+1] ⁺ : 488	142/166
545		MW: 491.66 MS (ESI) [M+1] ⁺ : 492	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
546	 2-Cyano-N-(2-dimethylamino-ethyl)-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-N-methyl-acetamide	MW: 496.68 MS (ESI) [M+1]⁺: 497	142/166
547		MW: 497.66 MS (ESI) [M+1]⁺: 498	142/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
548		MW: 503.62 MS (ESI) $[M+1]^+$: 504	142/166
549		MW: 529.71 MS (ESI) $[M+1]^+$: 530	142/166
550		MW: 529.71 MS (ESI) $[M+1]^+$: 530	142/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
551		MW: 532.71 MS (ESI) $[M+1]^+$: 533	142/166
552		MW: 533.67 MS (ESI) $[M+1]^+$: 534	142/166
553		MW: 517.70 MS (ESI) $[M+1]^+$: 518	142/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
554		MW: 541.72 MS (ESI) [M+1] ⁺ : 542	142/166
555	 2-Cyano-N-(1,1-dimethyl-2-phenyl-ethyl)- 2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-2-(E or Z)-ylidene]-acetamide	MW: 543.73 MS (ESI) [M+1] ⁺ : 544	142/166
556		MW: 540.73 MS (ESI) [M+1] ⁺ : 541	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
557		MW: 554.76 MS (ESI) $[M+1]^+$: 555	148 / 166
558		MW: 568.78 MS (ESI) $[M+1]^+$: 569	148 / 166
559		MW: 594.82 MS (ESI) $[M+1]^+$: 595	148 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
560		MW: 589.76 MS (ESI) [M+1] ⁺ : 590	 148 / 166
561		MW: 604.77 MS (ESI) [M+1] ⁺ : 605	 148 / 166
562		MW: 596.79 MS (ESI) [M+1] ⁺ : 597	 148 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
563	 4-(4-{{2-[1-Cyano-1-(2,3-dimethylcyclohexylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 608.85 MS (ESI) [M+1]⁺: 609	148 / 166
564		MW: 568.78 MS (ESI) [M+1]⁺: 569	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
565		MW: 614.77 MS (ESI) [M+1] ⁺ : 615	 148 / 166
566		MW: 616.83 MS (ESI) [M+1] ⁺ : 617	 148 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
567	 4-(4-{[2-[1-Cyano-2-oxo-2-(4-pyridin-2-yl-piperazin-1-yl)-eth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 644.84 MS (ESI) [M+1] ⁺ : 645	 148 / 166
568		MW: 673.88 MS (ESI) [M+1] ⁺ : 674	 148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
569		MW: 583.80 MS (ESI) [M+1] ⁺ : 584	148 / 166
570		MW: 614.81 MS (ESI) [M+1] ⁺ : 615	148 / 166
571		MW: 638.83 MS (ESI) [M+1] ⁺ : 639	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
572	 4-(4-{[2-[1-Cyano-1-(4-propyl-phenylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 616.83 MS (ESI) [M+1] ⁺ : 617	148 / 166
573		MW: 617.82 MS (ESI) [M+1] ⁺ : 618	148 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
574		MW: 628.84 MS (ESI) [M+1] ⁺ : 629	148 / 166
575	 4-(4-{[2-[1-Cyano-1-[3-(2-methyl-piperidin-1-yl)-propylcarbamoyl]-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 637.89 MS (ESI) [M+1] ⁺ : 638	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI)	Educt/ Synthe- sis as in the Case of
576		MW: 672.77 MS (ESI) [M+1] ⁺ : 673	148 / 166
577		MW: 566.77 MS (ESI) [M+1] ⁺ : 567	148 / 166
578		MW: 692.32 MS (ESI) [M+1] ⁺ : 693	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
579		MW: 616.83 MS (ESI) [M+1] ⁺ : 617	148 / 166
580	 4-(4-{{2-[2-[4-(4-Bromo-phenyl)-4-hydroxy-piperidin-1-yl]-1-cyano-2-oxo-ethylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 737.76 MS (ESI) [M+1] ⁺ : 738	148 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
581		MW: 592.76 MS (ESI) [M+1] ⁺ : 593	148 / 166
582		MW: 619.83 MS (ESI) [M+1] ⁺ : 620	148 / 166
583		MW: 620.79 MS (ESI) [M+1] ⁺ : 621	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
584		MW: 617.77 MS (ESI) [M+1] ⁺ : 618	148 / 166
585		MW: 700.95 MS (ESI) [M+1] ⁺ : 701	148 / 166
586		MW: 653.93 MS (ESI) [M+1] ⁺ : 654	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
587		MW: 666.84 MS (ESI) [M+1] ⁺ : 667	148 / 166
588	 4-(4-{[2-[1-Cyano-1-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 582.77 MS (ESI) [M+1] ⁺ : 583	148 / 166

Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
589		MW: 569.77 MS (ESI) [M+1] ⁺ : 570	148 / 166
590		MW: 609.84 MS (ESI) [M+1] ⁺ : 610	148 / 166
591		MW: 595.81 MS (ESI) [M+1] ⁺ : 596	148 / 166






Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
592		MW: 625.83 MS (ESI) [M+1] ⁺ : 626	148 / 166
593		MW: 638.88 MS (ESI) [M+1] ⁺ : 639	148 / 166
594		MW: 639.91 MS (ESI) [M+1] ⁺ : 640	148 / 166

Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
595		MW: 638.87 MS (ESI) [M+1] ⁺ : 639	148 / 166
596	 4-(4-{{2-[1-Cyano-1-(2-morpholin-4-yl-ethylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 611.81 MS (ESI) [M+1] ⁺ : 612	148 / 166







Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
597		MW: 611.85 MS (ESI) $[M+1]^+$: 612	148 / 166
598		MW: 637.89 MS (ESI) $[M+1]^+$: 638	148 / 166
599		MW: 645.87 MS (ESI) $[M+1]^+$: 646	148 / 166







Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
600		MW: 597.82 MS (ESI) [M+1] ⁺ : 598	 148 / 166
601		MW: 642.79 MS (ESI) [M+1] ⁺ : 643	 148 / 166
602		MW: 659.85 MS (ESI) [M+1] ⁺ : 660	 148 / 166







The following compounds can also be produced analogously to the synthesis of
Example 166.

Example	Structure
603	
604	
605	
606	
607	







Example	Structure
608	
609	
610	
611	
612	
613	

Example	Structure
614	
615	
616	
617	
618	
619	







Example	Structure
620	
621	
622	
623	
624	
625	







Example	Structure
626	
627	
628	
629	
630	
631	







Example	Structure
632	 <chem>CC1=C(C#N)C(=O)N(C1)C(=O)NCC2=CC=CC=C3C(=C2)C(=O)NCC4CCCC4C3=O</chem>
633	 <chem>CC1=C(C#N)C(=O)N(C1)C(=O)NCC2=CC=CC=C3C(=C2)C(=O)NCC4CCCC4C3=O</chem>
634	 <chem>CC1=C(C#N)C(=O)N(C1)C(=O)NCC2=CC=CC=C3C(=C2)C(=O)NCC4CCCC4C3=O</chem>
635	 <chem>CC1=C(C#N)C(=O)N(C1)C(=O)NCC2=CC=CC=C3C(=C2)C(=O)NCC4CCCC4C3=O</chem>
636	 <chem>CC1=C(C#N)C(=O)N(C1)C(=O)NCC2=CC=CC=C3C(=C2)C(=O)NCC4CCCC4C3=O</chem>
637	 <chem>CC1=C(C#N)C(=O)N(C1)C(=O)NCC2=CC=CC=C3C(=C2)C(=O)NCC4CCCC4C3=O</chem>







Example	Structure
638	 <chem>COCC(=O)N/C=C1\N(CC)C(=O)NC1NC(=O)NCCNC(=O)c2ccc3ccccc3cc2</chem>
639	 <chem>CC(C)C(=O)N/C=C1\N(CC)C(=O)NC1NC(=O)NCCNC(=O)c2ccc3ccccc3cc2</chem>
640	 <chem>O[C@@H](c1ccccc1)NC(=O)/C=C1\N(CC)C(=O)NC1NC(=O)NCCNC(=O)c2ccc3ccccc3cc2</chem>
641	 <chem>CN(C)CCNC(=O)/C=C1\N(CC)C(=O)NC1NC(=O)NCCNC(=O)c2ccc3ccccc3cc2</chem>
642	 <chem>C1CCNCC1NC(=O)/C=C1\N(CC)C(=O)NC1NC(=O)NCCNC(=O)c2ccc3ccccc3cc2</chem>
643	 <chem>CN1CCNCC1NC(=O)/C=C1\N(CC)C(=O)NC1NC(=O)NCCNC(=O)c2ccc3ccccc3cc2</chem>

[illegible]








Example	Structure
650	
651	
652	
653	
654	
655	

Example	Structure
656	
657	
658	
659	
660	
661	

Example	Structure
662	 <chem>CN(C)CCNC(=O)C1=C(C#N)N(CC)C(=O)N1CNc2ccc3ccccc3cc2C(=O)NCCN4CCCC4</chem>
663	 <chem>CC(C)CNC(=O)C1=C(C#N)N(CC)C(=O)N1CNc2ccc3ccccc3cc2C(=O)NCCN4CCCC4</chem>
664	 <chem>CCC(O)CNC(=O)C1=C(C#N)N(CC)C(=O)N1CNc2ccc3ccccc3cc2C(=O)NCCN4CCCC4</chem>
665	 <chem>C1=CC=CC=C1Nc2ccccc2C(=O)N1C(=O)N(CC)C(=O)N1CNc2ccc3ccccc3cc2C(=O)NCCN4CCCC4</chem>
666	 <chem>Oc1ccccc1C(=O)N1C(=O)N(CC)C(=O)N1CNc2ccc3ccccc3cc2C(=O)NCCN4CCCC4</chem>
667	 <chem>N#Cc1ccc(NC(=O)C1=C(C#N)N(CC)C(=O)N1CNc2ccc3ccccc3cc2C(=O)NCCN4CCCC4)cc1</chem>









Example	Structure
668	
669	
670	
671	
672	
673	

Example	Structure
674	
675	
676	
677	
678	
679	
680	

Example	Structure
681	 <chem>CC1(C#N)C(=S)C(CN1C(=O)NC2=CC=C(NC2C(=O)NCC3CCCC3)C4=CC=CC=C4)C5=CC=CC=C5C(=O)NCC6CCCC6</chem>
682	 <chem>CC1(C#N)C(=S)C(CN1C(=O)NC2=CC=C(NC2C(=O)NCC3CCCC3)C4=CC=CC=C4)C(=O)NCC(F)(F)F</chem>
683	 <chem>CC1(C#N)C(=S)C(CN1C(=O)NC2=CC=C(NC2C(=O)NCC3CCCC3)C4=CC=CC=C4)C(=O)NCCO</chem>
684	 <chem>CC1(C#N)C(=S)C(CN1C(=O)NC2=CC=C(NC2C(=O)NCC3CCCC3)C4=CC=CC=C4)C(=O)N(C)C</chem>
685	 <chem>CC1(C#N)C(=S)C(CN1C(=O)NC2=CC=C(NC2C(=O)NCC3CCCC3)C4=CC=CC=C4)C(=O)NC5=CC=C(F)C(F)=C5</chem>
686	 <chem>CC1(C#N)C(=S)C(CN1C(=O)NC2=CC=C(NC2C(=O)NCC3CCCC3)C4=CC=CC=C4)C(=O)NCC(C)C</chem>
687	 <chem>CC1(C#N)C(=S)C(CN1C(=O)NC2=CC=C(NC2C(=O)NCC3CCCC3)C4=CC=CC=C4)C(=O)NCC5CCNCC5</chem>








Files requested by : ADTN

5571978
8102913
8119366
8125592








Example	Structure
688	
689	
690	
691	
692	
693	
694	
695	








Example	Structure
696	
697	
698	
699	
700	
701	
702	
703	

Example	Structure
704	
705	
706	
707	
708	
709	
710	
711	








Example	Structure
712	
713	
714	
715	
716	
717	
718	








Example	Structure
719	
720	
721	
722	
723	
724	
725	








Example	Structure
726	
727	
728	
729	
730	
731	
732	

Example	Structure
733	
734	
735	
736	
737	
738	
739	

Example	Structure
740	
741	
742	
743	
744	
745	
746	

Example	Structure
747	
748	
749	
750	
751	
752	
753	







Example	Structure
754	
755	
756	
757	
758	
759	
760	







Example	Structure
761	
762	
763	
764	
765	
766	
767	







Example	Structure
768	
769	
770	
771	
772	
773	







Example	Structure
774	
775	
776	
777	
778	
779	







Example	Structure
780	 Detailed description: The structure consists of a central thiazolidine-4-carboxamide core. The nitrogen at position 2 is substituted with an ethyl group. At position 3, there is a cyano group (-C≡N). At position 4, there is a carboxamide group (-CONH-) linked to a 6-(2-hydroxyethyl)piperazine moiety. At position 5, there is another carboxamide group (-CONH-) linked to a 4-(2-(2-(pyrrolidin-2-ylethyl)amino)phenyl)benzoyl group.
781	 Detailed description: This structure is similar to 780 but lacks the hydroxymethyl group on the piperazine ring. Instead, it features a morpholine ring connected via its nitrogen atom to the amide carbonyl at position 4 of the thiazolidine core. The rest of the molecule remains identical to example 780.
782	 Detailed description: In this variant, the amide group at position 4 of the thiazolidine core is linked to a nicotinamide (vitamin B3) moiety instead of the piperazine derivative seen in 780. The other substituents are the same as in example 780.
783	 Detailed description: Here, the amide group at position 4 of the thiazolidine core is linked to a 2-methoxyethyl group (-CH2CH2OCH3). The remaining parts of the molecule are consistent with examples 780 through 782.
784	 Detailed description: In this case, the amide group at position 4 of the thiazolidine core is linked to a dimethylcarbamoyl group (-CONH-C(=O)-N(CH3)2). The other structural elements are unchanged from the previous examples.
785	 Detailed description: This structure is very similar to 782, featuring a pyridine ring. However, the connection between the thiazolidine core and the pyridine ring is via a 2-pyridylmethyl group (-CH2-pyridine), rather than a nicotinamide moiety as in 782.







Example	Structure
786	
787	
788	
789	
790	
791	

Example	Structure
792	
793	
794	
795	
796	
797	







Example	Structure
798	 <chem>CCN1C(=O)C(S1C(=O)CNC2=CC=C(C=C2)NC(=O)NCC3CCCN3)C(=C(C#N)C#N)NC(=O)NCC#N</chem>
799	 <chem>CCN1C(=O)C(S1C(=O)CNC2=CC=C(C=C2)NC(=O)NCC3CCCN3)C(=C(C#N)C#N)NC(=O)NCC(O)CC</chem>
800	 <chem>CCN1C(=O)C(S1C(=O)CNC2=CC=C(C=C2)NC(=O)NCC3CCCN3)C(=C(C#N)C#N)NC(=O)NCC4=CC=CC=N4</chem>
801	 <chem>CCN1C(=O)C(S1C(=O)CNC2=CC=C(C=C2)NC(=O)NCC3CCCN3)C(=C(C#N)C#N)NC(=O)Nc4ccccc4O</chem>
802	 <chem>CCN1C(=O)C(S1C(=O)CNC2=CC=C(C=C2)NC(=O)NCC3CCCN3)C(=C(C#N)C#N)NC(=O)Nc4ccc(C#N)cc4</chem>
803	 <chem>CCN1C(=O)C(S1C(=O)CNC2=CC=C(C=C2)NC(=O)NCC3CCCN3)C(=C(C#N)C#N)NC(=O)NCC4CCCCC4C#N</chem>







Example	Structure
804	
805	
806	
807	
808	
809	







Example	Structure
810	
811	
812	
813	
814	
815	

Example	Structure
816	 <chem>CC1=CN(C(=O)N1C(=S)NC2=CC=C(NC2=CC=C(NC(=O)CCN3CCN(C)CC3)C(=O)NCC4(F)(F)F)C#N)C(=O)NCC5(F)(F)F</chem>
817	 <chem>CC1=CN(C(=O)N1C(=S)NC2=CC=C(NC2=CC=C(NC(=O)CCN3CCN(C)CC3)C(=O)NCCO)C#N)C(=O)NCCO</chem>
818	 <chem>CC1=CN(C(=O)N1C(=S)NC2=CC=C(NC2=CC=C(NC(=O)CCN3CCN(C)CC3)C(=O)N(C)C)C#N)C(=O)N(C)C</chem>
819	 <chem>CC1=CN(C(=O)N1C(=S)NC2=CC=C(NC2=CC=C(NC(=O)CCN3CCN(C)CC3)C(=O)NCC4=CC=C(F)C=C4)C#N)C(=O)NCC5=CC=C(F)C=C5</chem>
820	 <chem>CC1=CN(C(=O)N1C(=S)NC2=CC=C(NC2=CC=C(NC(=O)CCN3CCN(C)CC3)C(=O)NCC(C)C)C#N)C(=O)NCC(C)C</chem>
821	 <chem>CC1=CN(C(=O)N1C(=S)NC2=CC=C(NC2=CC=C(NC(=O)CCN3CCN(C)CC3)C(=O)NCC4CCNCC4)C#N)C(=O)NCC5CCNCC5</chem>






Example	Structure
822	
823	
824	
825	
826	
827	

Example	Structure
828	
829	
830	
831	
832	
833	

Example	Structure
834	
835	
836	
837	
838	
839	

Example	Structure
840	
841	
842	
843	
844	
845	






[illegible]






Example	Structure
861	 <chem>CCN1C(=O)C(S1CNC(=O)c2ccc(NC(=O)CCN3CCCC3)cc2)C(=O)NC(=O)C#N</chem>
862	 <chem>CCN1C(=O)C(S1CNC(=O)c2ccc(NC(=O)CCN3CCCC3)cc2)C(=O)NC(=O)C#N</chem>
863	 <chem>CCN1C(=O)C(S1CNC(=O)c2ccc(NC(=O)CCN3CCCC3)cc2)C(=O)NC(=O)C#N</chem>
864	 <chem>CCN1C(=O)C(S1CNC(=O)c2ccc(NC(=O)CCN3CCCC3)cc2)C(=O)NC(=O)C#N</chem>
865	 <chem>CCN1C(=O)C(S1CNC(=O)c2ccc(NC(=O)CCN3CCCC3)cc2)C(=O)NC(=O)C#N</chem>

Example	Structure
866	
867	
868	
869	
870	






Example	Structure
871	
872	
873	
874	
875	

Example	Structure
876	
877	
878	
879	
880	






Example	Structure
886	 Chemical structure of compound 886: A thiazolidine-2,4-dione derivative. The 2-position is substituted with a 4-(2-(pyrrolidin-1-yl)ethyl)benzamide group. The 4-position is substituted with a 1-ethoxypropyl group. The 5-position is substituted with a 1-ethyl-1,1-dicyano-2-oxoethyl group.
887	 Chemical structure of compound 887: A thiazolidine-2,4-dione derivative. The 2-position is substituted with a 4-(2-(pyrrolidin-1-yl)ethyl)benzamide group. The 4-position is substituted with a 1-hydroxy-2-methylpropyl group. The 5-position is substituted with a 1-ethyl-1,1-dicyano-2-oxoethyl group.
888	 Chemical structure of compound 888: A thiazolidine-2,4-dione derivative. The 2-position is substituted with a 4-(2-(pyrrolidin-1-yl)ethyl)benzamide group. The 4-position is substituted with a 2-(pyridin-2-yl)ethyl group. The 5-position is substituted with a 1-ethyl-1,1-dicyano-2-oxoethyl group.
889	 Chemical structure of compound 889: A thiazolidine-2,4-dione derivative. The 2-position is substituted with a 4-(2-(pyrrolidin-1-yl)ethyl)benzamide group. The 4-position is substituted with a 1-pyridin-2-yl group. The 5-position is substituted with a 1-ethyl-1,1-dicyano-2-oxoethyl group.
890	 Chemical structure of compound 890: A thiazolidine-2,4-dione derivative. The 2-position is substituted with a 4-(2-(pyrrolidin-1-yl)ethyl)benzamide group. The 4-position is substituted with a 1-propyl group. The 5-position is substituted with a 1-ethyl-1,1-dicyano-2-oxoethyl group.







Example	Structure
891	
892	
893	
894	
895	








Example	Structure
896	
897	
898	
899	
900	








Example	Structure
901	
902	
903	
904	
905	








Example	Structure
906	 <chem>CN(C)CCNC(=O)c1ccc(NC2CC(=O)N(C2)C#N)cc1</chem>
907	 <chem>CN(C)CCNC(=O)c1ccc(NC2CC(=O)N(C2)C#N)cc1</chem>
908	 <chem>CCN(C)CCNC(=O)c1ccc(NC2CC(=O)N(C2)C#N)cc1</chem>
909	 <chem>CCN(C)CCNC(=O)c1ccc(NC2CC(=O)N(C2)C#N)cc1</chem>
910	 <chem>CCN(C)CCNC(=O)c1ccc(NC2CC(=O)N(C2)C#N)cc1</chem>








Example	Structure
911	
912	
913	
914	
915	








Example	Structure
916	
917	
918	
919	
920	
921	







Example	Structure
922	
923	
924	
925	
926	
927	
928	

Example	Structure
929	
930	
931	
932	
933	
934	
935	






Example	Structure
936	
937	
938	
939	
940	
941	
942	

Example	Structure
943	
944	
945	
946	
947	
948	
949	

Example	Structure
950	
951	
952	
953	
954	
955	
956	

Example	Structure
957	
958	
959	
960	
961	
962	

Example	Structure
963	
964	
965	
966	
967	
968	
969	
970	
971	
972	
973	

Example	Structure
974	
975	
976	
977	
978	

Example 1

The following examples describe the biological action of the compounds according to the invention:

PLK Enzyme Assay

Recombinant human Plk-1 (6xHis) was purified from baculovirus-infected insect cells (Hi5).

10 ng of (produced in a recombinant manner and purified) PLK enzyme is incubated for 90 minutes at room temperature with biotinylated casein and 33P- γ -ATP as a substrate in a volume of 15 μ l in 384-well Greiner small-volume microtiter plates (final concentrations in the buffer: 660 ng/ml of PLK; 0.7 μ mol of casein, 0.5 μ mol of ATP incl. 400 nCi/ml of 33P- γ -ATP; 10 mmol of MgCl₂, 1 mmol of MnCl₂; 0.01% NP40; 1 mmol of DTT, protease inhibitors; 0.1 mmol of Na₂VO₃ in 50 mmol of HEPES, pH 7.5). To complete the reaction, 5 μ l of stop solution (500 μ mol of ATP; 500 mmol of EDTA; 1% Triton X100; 100 mg/ml of streptavidin-coated SPA beads in PBS) is added. After the microtiter plate is sealed by film, the beads are sedimented by centrifuging (10 minutes, 1500 rpm). The incorporation of 33P- γ -ATP in casein is intended as a measurement of enzyme activity by β -counting. The extent of the inhibitor activity is referenced against a solvent control (= uninhibited enzyme activity = 0% inhibition) and the mean value of several batches that contained 300 μ mol of wortmannin (= completely inhibited enzyme activity = 100% inhibition).







Test substances are used in various concentrations (0 μ mol, as well as in the range of 0.01 - 30 μ mol). The final concentration of the solvent dimethyl sulfoxide is 1.5% in all batches.


Proliferation Assay

Cultivated human MaTu breast tumor cells were flattened out at a density of 5000 cells/measuring point in a 96-well multititer plate in 200 μ l of the corresponding growth medium. After 24 hours, the cells of one plate (zero-point plate) were colored with crystal violet (see below), while the medium of the other plates was replaced by fresh culture medium (200 μ l), to which the test substances were added in various concentrations (0 μ m, as well as in the range of 0.01-30 μ m; the final concentration of the solvent dimethyl sulfoxide was 0.5%). The cells were incubated for 4 days in the presence of test substances. The cell proliferation was determined by coloring the cells with crystal violet: the cells were fixed by adding 20 μ l/measuring point of an 11% glutaric aldehyde solution for 15 minutes at room temperature. After three washing cycles of the fixed cells with water, the plates were dried at room temperature. The cells were colored by adding 100 μ l/measuring point of a 0.1% crystal violet solution (pH was set at 3 by adding acetic acid). After three washing cycles of the colored cells with water, the plates were dried at room temperature. The dye was dissolved by adding 100 μ l/measuring point of a 10% acetic acid solution. The extinction was determined by photometry at a wavelength of 595 nm. The change of cell growth, in percent, was calculated by standardization of the measured values to the extinction values of the zero-point plate (=0%) and the extinction of the untreated (0 μ m) cells (=100%).

The results of the PLK enzyme assay are presented in Table 1 below:




Table 1:

Example No.	Structure	PLK IC ₅₀ [nM]
25		36
7		46
36		160
19		500
56		810
234		950

Example No.	Structure	PLK IC50 [nM]
223		3100

The results of other PLK enzyme assays and the proliferation assay are presented in Tables 2 and 3 below:

Table 2: Amides

Example No.	Structure	Inhibition of Plk-1 IC50 [nM]	Inhibition of Tumor Cell Proliferation (MaTu) IC50 [μ M]
527		100	2.8
310		74	5.6
307		71	1.7









Example No.	Structure	Inhibition of Plk-1 IC50 [nM]	Inhibition of Tumor Cell Proliferation (MaTu) IC50 [μ M]
330		41	1.2
169		345	3.55
192		190	9.7
210		270	4.5

Table 3: Esters

Example No.	Structure	Inhibition of Plk-1 IC50 [nM]	Inhibition of Tumor Cell Proliferation (MaTu) IC50 [μ M]
133		34	1.4

Example No.	Structure	Inhibition of Plk-1 IC50 [nM]	Inhibition of Tumor Cell Proliferation (MaTu) IC50 [μ M]
132		81	3.1
47		23	1.1
74		37	3.3

Tables 1 to 3 show that the compounds according to the invention inhibit PLK in the nanomolar range.

Description of the Figure

Fig. 1 shows the function of Plk-1

Here:

1. Entry into mitosis: Plk-1 activates CDC25 C. This results in the activation of the CDK/cyclin B complex and converts the cell from G2 to M-status.
2. Triggering of mitosis: Plk 1 plays an important role during the cytokinesis, especially in the formation of the bipolar spindle apparatus and the chromosome separation during the late mitosis phase. Plk-1 is also required during centrosome maturation and binds to so-called 'kinesin motors.'
3. Completion of mitosis: Plk-1 activates the APC/C complex (anaphase promoting complex/cyclosome; Kotani et al. 1998;). APC/C catalyzes as E3-enzyme the polyubiquitinylation of specific substrates, such as, e.g., cyclin B. Such an ubiquitinylation of proteins ultimately results in their degradation into proteasomes. This in turn leads to a reduction of cell-cycle regulators below a critical value and in the exit from the mitosis phase in the so-called G1-status of the cell (M→G1 transition).

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

In the foregoing and in the examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.


The entire disclosures of all applications, patents and publications, cited herein and of corresponding Germany Application No. 10351744.8-44, filed October 31, 2003, and U.S. Provisional Application Serial No. 60/517,061, filed November 5, 2003 are incorporated by reference herein.

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

1. Compounds of general formula I



(I),

in which

Q stands for aryl or heteroaryl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro,

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for $-\text{NR}^3(\text{CO})-\text{L}$, $-\text{NR}^3(\text{CO})-\text{NR}^3-\text{L}$, $-\text{COR}^6$, $-\text{CO}(\text{NR}^3)-\text{M}$, $-\text{NR}^3(\text{CS})\text{NR}^3\text{R}^4$,
 $-\text{NR}^3\text{SO}_2-\text{M}$, $-\text{SO}_2-\text{NR}^3\text{R}^4$ or $-\text{SO}_2(\text{NR}^3)-\text{M}$,

- L** stands for $\text{C}_1\text{-C}_6$ -alkyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with $\text{C}_1\text{-C}_6$ -hydroxyalkoxy, $\text{C}_1\text{-C}_6$ -alkoxyalkoxy, $\text{C}_3\text{-C}_6$ -heterocycloalkyl or with the group $-\text{NR}^3\text{R}^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(\text{CO})-$ or $-\text{SO}_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_3\text{-C}_6$ -cycloalkyl, $\text{C}_1\text{-C}_6$ -hydroxyalkyl or with the group $-\text{NR}^3\text{R}^4$,
- M** stands for $\text{C}_1\text{-C}_6$ -alkyl that is optionally substituted in one or more places, in the same way or differently, with the group $-\text{NR}^3\text{R}^4$ or $\text{C}_3\text{-C}_6$ -heterocycloalkyl,
- X** stands for $-\text{NH}-$ or $-\text{NR}^5-$,
- R¹** stands for $\text{C}_1\text{-C}_4$ -alkyl, C_3 -cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,
- R²** stands for hydrogen or for $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_1\text{-C}_6$ -alkoxy, $\text{C}_1\text{-C}_6$ -alkenyl, $\text{C}_1\text{-C}_6$ -alkinyl, $\text{C}_3\text{-C}_6$ -cycloalkyl, $\text{C}_3\text{-C}_6$ -heterocycloalkyl, aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_1\text{-C}_6$ -alkoxy, $\text{C}_1\text{-C}_6$ -hydroxyalkyl, $\text{C}_3\text{-C}_6$ -cycloalkyl, $\text{C}_3\text{-C}_6$ -heterocycloalkyl, $\text{C}_1\text{-C}_6$ -alkinyl, aryl, aryloxy, heteroaryl or with the group $-\text{S-C}_1\text{-C}_6\text{-alkyl}$, $-\text{COR}^6$, $-\text{NR}^3\text{R}^4$, $-\text{NR}^3(\text{CO})-\text{L}$ or $-\text{NR}^3\text{COOR}^7$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(\text{CO})-$ or $-\text{SO}_2-$ groups in the ring, and/or

optionally one or more double bonds can be contained in the ring, and whereby aryl, heteroaryl, C₃-C₆-cycloalkyl- and/or the C₃-C₆-heterocycloalkyl ring in each case itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl or C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl, benzyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen,

or

for the group -NR³R⁴, -NR³(CO)-L, or -NR³(CS)NR³R⁴,

or

R² and R⁵ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted at least one time by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more-(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl or with the group -NR³R⁴ or -COR⁶, and/or can be substituted with aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, C₁-C₆-alkoxy or with the group -COR⁶,

R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, -CO-C₁-C₆-alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or

more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C_3 - C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C_1 - C_6 -alkyl, C_1 - C_6 -hydroxyalkyl, C_1 - C_6 -alkoxy, C_3 - C_6 -cycloalkyl, or with the group $-NR^3R^4$ or $-CO-NR^3R^4$,

or

R^3 and R^4 together form a C_3 - C_6 -heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring,

and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_1 - C_6 -hydroxyalkyl, C_1 - C_6 -alkoxyalkyl, cyano, hydroxy or with the group $-NR^3R^4$,

R^5 stands for C_1 - C_6 -alkyl, C_1 - C_6 -alkenyl, or C_1 - C_6 -alkinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C_1 - C_6 -alkoxy, C_3 - C_6 -cycloalkyl, C_3 - C_6 -heterocycloalkyl, or with the group $-NR^3R^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C_3 - C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with

cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

R⁶ stands for hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy or the group -NR³R⁴,

R⁷ stands for -(CH₂)_n-aryl or -(CH₂)_n-heteroaryl and

n stands for 1 - 6,

as well as their stereoisomers, diastereomers, enantiomers and salts,

with the stipulation that the following compounds do not fall under general formula (I):

{2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetyl-amino}-acetic acid methyl ester,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-pyridin-3-ylmethyl-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(3-imidazol-1-yl-propyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(4-fluoro-benzyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(3-morpholin-4-yl-propyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(2-morpholin-4-yl-ethyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-acetamide,

2-Cyano-N-cyclohexyl-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

4-{2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetyl-amino}-piperidine-1-carboxylic acid ethyl ester,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(3-hydroxy-propyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(4-methoxy-benzyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-[2-(4-hydroxy-phenyl)-ethyl]-acetamide,

N-Allyl-2-cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(2-hydroxy-ethyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(4-hydroxy-butyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(6-hydroxy-hexyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

2-Cyano-2-[3-ethyl-5-[1-(4-methoxy-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide,

6-{[2-[1-Cyano-1-dimethylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-naphthalene-2-carboxylic acid,

4-{[2-[1-Cyano-1-dimethylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-benzoic acid,

2-Cyano-2-[3-ethyl-5-[1-(4-hydroxy-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide,

4-{[2-[1-Cyano-1-dimethylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-benzamide,

2-Cyano-2-[3-ethyl-5-[1-(4-hydroxymethyl-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide.

2. Compounds of general formula I, according to claim 1, in which

Q stands for phenyl, naphthyl, quinolinyl, benzimidazolyl, indolyl, indazolyl, thiazolyl, imidazolyl or pyridyl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for -NR³(CO)-L, -NR³(CO)-NR³-L, -COR⁶, -CO(NR³)-M, -NR³(CS)NR³R⁴, -NR³SO₂-M, -SO₂-NR³R⁴ or -SO₂(NR³)-M,

L stands for C₁-C₆-alkyl or heteroaryl that is optionally substituted in one or

- more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-C₆-alkoxyalkoxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,
- M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -NR³R⁴ or C₃-C₆-heterocycloalkyl,
- X stands for -NH- or -NR⁵-,
- R¹ stands for C₁-C₄-alkyl, C₃-cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,
- R² stands for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-alkenyl, C₁-C₆-alkinyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-hydroxyalkyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, C₁-C₆-alkinyl, aryl, aryloxy, heteroaryl or with the group -S-C₁-C₆-alkyl, -COR⁶, -NR³R⁴, -NR³(CO)-L or -NR³COOR⁷, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby aryl, heteroaryl, C₃-C₆-cycloalkyl- and/or the C₃-C₆-heterocycloalkyl ring in each case itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-

C₆-alkyl, C₁-C₆-hydroxyalkyl, or C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl, benzyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen,

or

for the group -NR³R⁴, -NR³(CO)-L, or -NR³(CS)NR³R⁴,

or

R² and R⁵ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl or with the group -NR³R⁴ or -COR⁶, and/or with aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, C₁-C₆-alkoxy or with the group -COR⁶,

R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, -CO-C₁-C₆-alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in

the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

or

R³ and R⁴ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted by nitrogen at least once and optionally can be interrupted in one or more places by oxygen or sulfur, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl, cyano, hydroxy or with the group -NR³R⁴,

R⁵ stands for C₁-C₆-alkyl, C₁-C₆-alkenyl, or C₁-C₆-alkinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

R⁶ stands for hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy or the group -NR³R⁴,

R⁷ stands for -(CH₂)_n-aryl or -(CH₂)_n-heteroaryl and

n stands for 1 - 6,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

3. Compounds of general formula I, according to claim 1 or 2, in which

Q stands for phenyl, naphthyl or indolyl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for -NR³(CO)-L, -NR³(CO)-NR³-L, -COR⁶, -CO(NR³)-M, -NR³(CS)NR³R⁴, -NR³SO₂-M, -SO₂-NR³R⁴ or -SO₂(NR³)-M,

L stands for C₁-C₆-alkyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-C₆-alkoxyalkoxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be

- substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,
- M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -NR³R⁴ or C₃-C₆-heterocycloalkyl,
- X stands for -NH- or -NR⁵-,
- R¹ stands for C₁-C₄-alkyl, C₃-cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,
- R² stands for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-alkenyl, C₁-C₆-alkinyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-hydroxyalkyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, C₁-C₆-alkinyl, aryl, aryloxy, heteroaryl or with the group -S-C₁-C₆-alkyl, -COR⁶, -NR³R⁴, -NR³(CO)-L or -NR³COOR⁷,
- whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring,
- and whereby aryl, heteroaryl, C₃-C₆-cycloalkyl- and/or the C₃-C₆-heterocycloalkyl ring in each case itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, or C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl, benzyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen,
- or
- for the group -NR³R⁴, -NR³(CO)-L, or -NR³(CS)NR³R⁴,

or

R^2 and R^5 together form a C_3 – C_6 -heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C_1 – C_6 -alkyl, C_3 – C_6 -cycloalkyl, C_1 – C_6 -hydroxyalkyl, C_1 – C_6 -alkoxyalkyl or with the group $-NR^3R^4$ or $-COR^6$, and/or can be substituted with aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, C_1 – C_6 -alkoxy or with the group $-COR^6$,

R^3 and R^4 , independently of one another, stand for hydrogen or for C_1 – C_6 -alkyl, C_1 – C_6 -alkoxy, $-CO-C_1$ – C_6 -alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C_3 – C_6 -heterocycloalkyl, C_1 – C_6 -hydroxyalkoxy or with the group $-NR^3R^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C_3 – C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C_1 – C_6 -alkyl, C_1 – C_6 -hydroxyalkyl, C_1 – C_6 -alkoxy, C_3 – C_6 -cycloalkyl, or with the group $-NR^3R^4$ or $-CO-NR^3R^4$,

or

R^3 and R^4 together form a C_3 – C_6 -heterocycloalkyl ring, which is interrupted at least

once by nitrogen, and optionally can be interrupted in one or more places by oxygen or sulfur, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring,

and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C_1-C_6 -alkyl, C_3-C_6 -cycloalkyl, C_1-C_6 -hydroxyalkyl, C_1-C_6 -alkoxyalkyl, cyano, hydroxy or with the group $-NR^3R^4$,

R^5 stands for C_1-C_6 -alkyl, C_1-C_6 -alkenyl, or C_1-C_6 -alkinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C_1-C_6 -alkoxy, C_3-C_6 -cycloalkyl, C_3-C_6 -heterocycloalkyl, or with the group $-NR^3R^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C_3-C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C_1-C_6 -alkyl, C_1-C_6 -hydroxyalkyl, C_1-C_6 -alkoxy, C_3-C_6 -cycloalkyl, or with the group $-NR^3R^4$ or $-CO-NR^3R^4$,

R^6 stands for hydroxy, C_1-C_6 -alkyl, C_1-C_6 -alkoxy or the group $-NR^3R^4$,

R^7 stands for $-(CH_2)_n$ -aryl or $-(CH_2)_n$ -heteroaryl and

n stands for 1 - 6,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

4. Compounds of general formula I, according to one of the above-mentioned claims, in which

Q stands for phenyl, naphthyl or indolyl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with pyrrolidinyl, piperidinyl, piperazinyl or with the group -N(C₁-C₆-alkyl)₂, whereby pyrrolidinyl, piperidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl or C₁-C₆-hydroxyalkyl, or

for -CO(NH)-M, -CO(NCH₃)-M, -NH(CO)-L, -NH(CO)-NH-L, -SO₂(NH)-M or -SO₂(NCH₃)-M,

L stands for C₁-C₆-alkyl or pyridyl that is optionally substituted in one or more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-C₆-alkoxyalkoxy, pyrrolidinyl, piperazinyl or with the group -N(C₁-C₆-alkyl)₂, whereby the pyrrolidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl,

M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -N(C₁-C₆-alkyl)₂ or pyrrolidinyl,

X stands for -NH- or -NR⁵-,

R¹ stands for C₁-C₄-alkyl that is optionally substituted in one or more places, in the same way or differently, with halogen,

R² stands for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkenyl, C₁-C₆-alkinyl, C₃-C₆-cycloalkyl, pyrrolidinyl, piperidinyl, phenyl, tetralinyl or indolyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-hydroxyalkyl, C₃-C₆-cycloalkyl, tetrahydrofuranyl, pyrrolidinyl, piperazinyl, morpholinyl,

phenyl, phenoxy, biphenyl, naphthyl, thienyl, furanyl, tetrazolyl, pyridyl or with the group $-S-C_1-C_6\text{-alkyl}$, $-\text{CONH}_2$, $-\text{COO}-C_1-C_6\text{-alkyl}$, $-\text{N}(C_1-C_6\text{-alkyl})_2$, $-\text{N}(C_1-C_6\text{-alkyl})\text{phenyl}$, or $-\text{NH}(\text{CO})-\text{L}$,

whereby phenyl, furanyl, $C_3-C_6\text{-cycloalkyl}$, piperidinyl or piperazinyl in each case itself optionally can be substituted in one or more places, in the same way or differently, with $C_1-C_6\text{-alkyl}$, $C_1-C_6\text{-alkoxy}$, cyano, halogen, hydroxy, phenyl, benzyl, or morpholinyl, and the $C_1-C_6\text{-alkyl}$ or $C_1-C_6\text{-alkoxy}$ itself optionally can be substituted in one or more places, in the same way or differently, with halogen,

or

for the group $-\text{N}(C_1-C_6\text{-alkyl})_2$, $-\text{NH}(\text{CO})-\text{L}$, or $-\text{NCH}_3(\text{CS})\text{NHCH}_3$,

or

R^2 and R^5 together form aziridinyl, azetidiny, morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl, whereby aziridinyl, azetidiny, morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with hydroxy, $C_1-C_6\text{-alkyl}$, $C_1-C_6\text{-hydroxyalkyl}$, $C_1-C_6\text{-alkoxyalkyl}$ or with the group $-\text{CONH}_2$, $-\text{CO}-C_1-C_6\text{-alkyl}$ or $-\text{COO}-C_1-C_6\text{-alkyl}$, and/or can be substituted with phenyl, benzyl or pyridyl that is optionally substituted in one or more places, in the same way or differently, with halogen or $C_1-C_6\text{-alkoxy}$, and

R^5 stands for $C_1-C_6\text{-alkyl}$ or $C_1-C_6\text{-alkenyl}$ that is optionally substituted in one or more places, in the same way or differently, with $C_1-C_6\text{-alkoxy}$,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

5. Compounds of general formula (I), according to the above-mentioned claims, in which

Q stands for phenyl, naphthyl or indolyl,


A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro,

or




for C₁-C₃-alkyl or C₁-C₃-alkoxy that is optionally substituted in one or more places, in the same way or differently, with pyrrolidinyl, piperidinyl, piperazinyl or with the group -N(CH₃)₂ or -CO(NH)-(CH₂)₂-N(CH₃)₂, whereby pyrrolidinyl, piperidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₃-alkyl or C₁-C₃-hydroxyalkyl,

or

for the group -CO-NH-(CH₂)₂-N(CH₃)₂, -CO-NH-(CH₂)₂-N(C₂H₅)₂, -CO-N(CH₃)-(CH₂)₂-N(CH₃)₂,



-NH(CO)-C(CH₃)₃, -NH(CO)-(CH₂)-O(CH₂)₂-OCH₃, -NH(CO)-(CH₂)₂-N(C₂H₅)₂,



or $-\text{SO}_2\text{-NH-(CH}_2)_2\text{-N(CH}_3)_2$ or $-\text{SO}_2\text{-N(CH}_3\text{)-(CH}_2)_2\text{-N(CH}_3)_2$,

X stands for $-\text{NH-}$ or $-\text{NR}^5\text{-}$,

R^1 stands for $\text{C}_1\text{-C}_3\text{-alkyl}$ that is optionally substituted in one or more places, in the same way or differently, with halogen,


R^2 stands for hydrogen or for $\text{C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_1\text{-C}_4\text{-alkenyl}$, $\text{C}_1\text{-C}_4\text{-alkinyl}$, $\text{C}_3\text{-C}_6\text{-cycloalkyl}$, piperidinyl, phenyl, pyrrolidinyl, indolyl or tetralinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, $\text{C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_1\text{-C}_6\text{-hydroxyalkyl}$, methoxy, $\text{C}_3\text{-C}_6\text{-cycloalkyl}$, tetrahydrofuranyl, pyrrolidinyl, piperazinyl, morpholinyl, phenyl, phenoxy, biphenyl, naphthyl, thienyl, furanyl, tetrazolyl or pyridyl or with the group $-\text{S-CH}_3$, $-\text{COOCH}_3$, $-\text{COOC}_2\text{H}_5$, $-\text{CO-NH}_2$, $-\text{OCF}_3$, $-\text{N(CH}_3\text{)-phenyl}$, $-\text{N(C}_1\text{-C}_4\text{-alkyl)}_2$, or $-\text{NH(CO)-CH}_3$, whereby phenyl, furanyl, $\text{C}_3\text{-C}_6\text{-cycloalkyl}$, piperidinyl or piperazinyl optionally in each case itself can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, $\text{C}_1\text{-C}_3\text{-alkyl}$, $\text{C}_1\text{-C}_3\text{-hydroxyalkyl}$, methoxy, morpholinyl, phenyl or benzyl,

or

for the group $-\text{N(CH}_3)_2$, $-\text{N(CH}_3\text{)(CS)NHCH}_3$, $-\text{NH(CO)-CH}_3$, $-\text{NH(CO)-pyridyl}$, or $-\text{NH(CO)-pyridinyl}$,

or

R^2 and R^5 together form one of the following rings:




[or]

and

R⁵ stands for C₁-C₃-alkyl or C₁-C₃-alkenyl that is optionally substituted in one or

more places, in the same way or differently, with C_1 - C_6 -alkoxy, as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

6. Compounds of general formula IA



in which

Q stands for aryl or heteroaryl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro

or

for C_1 - C_3 -alkyl or C_1 - C_6 -alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C_3 - C_6 -heterocycloalkyl or with the group $-NR^3R^4$ or $-CO(NR^3)-M$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_1 - C_6 -hydroxyalkyl or with the group $-NR^3R^4$,

or

for $-NR^3(CO)-L$, $-NR^3(CO)-NR^3-L$, $-COR^6$, $-CO(NR^3)-M$, $-NR^3(CS)NR^3R^4$, $-NR^3SO_2-M$, $-SO_2-NR^3R^4$ or $-SO_2(NR^3)-M$,

L stands for C_1 - C_6 -alkyl or heteroaryl that is optionally substituted in one or

- more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-C₆-alkoxyalkoxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,
- M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -NR³R⁴ or C₃-C₆-heterocycloalkyl,
- R¹ stands for C₁-C₄-alkyl, C₃-cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,
- R^{2a} stands for allyl or propargyl,
- R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, -CO-C₁-C₆-alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,
- or

R^3 and R^4 together form a C_3 - C_6 -heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring,

and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_1 - C_6 -hydroxyalkyl, C_1 - C_6 -alkoxyalkyl, cyano, hydroxy or with the group $-NR^3R^4$, and

R^6 stands for hydroxy, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy or the group $-NR^3R^4$, as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

7. Compounds of general formula IA, according to claim 6, in which

Q stands for phenyl, quinolinyl, indolyl or naphthyl,

A and B, independently of one another, stand for hydrogen or halogen,

or

for C_1 - C_3 -alkyl or C_1 - C_6 -alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy or with the group $-NC_1-C_6-alkyl)_2$ or $-CO(NH)-M$,

or

for $-NH(CO)-L$, $-NH(CO)-NH-L$, $-COR^6$, $-CO(NH)-M$, $-CO(NCH_3)-M$, $-SO_2(NH)-M$ or $-SO_2(NCH_3)-M$,

L stands for C_1 - C_6 -alkyl that is optionally substituted in one or more places, in the same way or differently, with pyrrolidinyl,

M stands for C_1 - C_6 -alkyl that is optionally substituted in one or more places, in the same way or differently, with the group $-N(C_1-C_6-alkyl)_2$ or pyrrolidinyl,

R¹ stands for C₁-C₃-alkyl,

R^{2a} stands for allyl or propargyl, and

R⁶ stands for hydroxy, C₁-C₆-alkyl or C₁-C₆-alkoxy,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

8. Compounds of the following formulas, as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts:

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[4-(2-morpholin-4-yl-ethanesulfonylamino)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-({4-[(pyrrolidine-1-carbonyl)-amino]-phenylamino}-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-({4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene)-acetic acid allyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-({4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene)-acetic acid benzyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{4-(2-pyrrolidin-1-yl-ethylcarbamoyl)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid allyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(p-tolylamino-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(m-tolylamino-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(3-nitro-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(3-Chloro-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester,

5-{[2-((E or Z)-Cyano-ethoxycarbonyl-methylene)-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl]-amino}-1H-indole-2-carboxylic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-methyl-1H-indol-5-ylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(3-Carbamoyl-1H-indol-5-ylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[3-(4-methyl-piperazine-1-carbonyl)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({3-[2-(2-hydroxymethyl-pyrrolidin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[3-(2-piperidin-1-yl-ethanesulfonylamino)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[3-(2-pyrrolidin-1-yl-ethanesulfonylamino)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[4-(3-methoxy-propionylamino)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(2-methoxy-ethoxy)-acetylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[4-(2-methoxy-acetylamino)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[4-(2-piperidin-1-yl-ethanesulfonylamino)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(4-methyl-piperazin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-methanesulfonylamino-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(2-hydroxymethyl-piperidin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(2-hydroxymethyl-pyrrolidin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid propyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-fluoro-4-hydroxy-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(3-Chloro-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-3-nitro-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{5-(E/Z)-[(3,5-dichloro-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-3,5-dimethyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{5-(E/Z)-[(3-diethylaminomethyl-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-3-methyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{5-(E/Z)-[(3,5-dibromo-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

5-{[2-((E or Z)-Cyano-ethoxycarbonyl-methylene)-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl]-amino}-2-hydroxy-benzoic acid methyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-hydroxy-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-fluoro-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(o-tolylamino-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(2-Chloro-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(quinolin-8-ylaminomethylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-isopropyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-(naphthalen-1-ylaminomethylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-(naphthalen-1-ylaminomethylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-ethyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(1H-Benzimidazol-2-ylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(1-methyl-1H-benzimidazol-2-ylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

Cyano-[3-ethyl-4-oxo-5-[1-[4-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester,

Cyano-[3-ethyl-4-oxo-5-[1-{4-[3-(2-pyrrolidin-1-yl-ethyl)-ureido]-phenylamino}-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester,

4-(4-{[2-[1-Allyloxycarbonyl-1-cyano-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/ Z)-ylidenemethyl]-amino}-phenyl)-butyric acid,

Cyano-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester,

4-{[2-[1-Allyloxycarbonyl-1-cyano-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/ Z)-ylidenemethyl]-amino}-benzoic acid,

6-{[2-[1-Allyloxycarbonyl-1-cyano-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/ Z)-ylidenemethyl]-amino}-naphthalene-2-carboxylic acid,

Cyano-[5-[1-{4-[3-(2-diethylamino-ethylcarbamoyl)-propyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester,

Cyano-[3-ethyl-4-oxo-5-[1-[6-(2-pyrrolidin-1-yl-ethylcarbamoyl)-naphthalen-2-ylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[3-(2-hydroxy-ethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-({4-[(pyrrolidin-1-carbonyl)-amino]-phenylamino}-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-methoxy-3-[(morpholin-4-carbothioyl)-amino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[4-{3-[2-(2-hydroxy-ethoxy)-ethyl]-ureido-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[(4-methyl-piperazin-1-carbothioyl)-amino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[3-(2-hydroxy-ethyl)-thioureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[4-Acetylsulfamoyl-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyanoacetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-{3-[2-(2-hydroxy-ethoxy)-ethyl]-thioureido}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[2-(2-hydroxy-ethyl)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester,

Cyano-{3-ethyl-5-(E/Z)-[(2-ethyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-fluoro-3-[3-(2-morpholin-4-yl-ethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[3-(1-ethyl-pyrrolidin-2-ylmethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-{[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-amino}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({3-[3-(2-morpholin-4-yl-ethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[5-(E/Z)-({3-[3-(3-dimethylamino-propyl)-ureido]-phenylamino}-methylene)-3-ethyl-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-{[4-(4-methyl-piperazin-1-yl)-piperidine-1-carbonyl]-amino}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[5-(E/Z)-({4-[3-(3-dimethylamino-propyl)-ureido]-phenylamino}-methylene)-3-ethyl-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[5-(E/Z)-({3-[3-(3-dimethylamino-propyl)-ureido]-4-fluoro-phenylamino}-methylene)-3-ethyl-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,


(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-fluoro-3-{3-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-ureido}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-fluoro-3-{[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-amino}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-({4-[3-(2-pyrrolidin-1-yl-ethyl)-ureido]-phenylamino}-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[(4-methyl-piperazine-1-carbonyl)-amino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester.


9. Uses of the compounds of general formula IIA or IIB



[or]

in which D stands for the group $-\text{NO}_2$, $-\text{NH}_2$ or $-\text{NH}(\text{CO})\text{OC}(\text{CH}_3)_3$ and E stands for $\text{C}_1\text{-C}_6$ -alkoxy or halogen, and R^3 and R^4 have the meaning that is described in general formula I, as intermediate products for the production of the substances of general formula I according to the invention.


10. Uses of the compounds of general formula IIIA or IIIB



[or]


in which D stands for the group $-\text{NO}_2$, $-\text{NH}_2$ or $-\text{NH}(\text{CO})\text{OC}(\text{CH}_3)_3$, and G stands for the group $-\text{NR}^3\text{R}^4$, and R^3 , R^4 and n have the meaning that is described in general formula I, as intermediate products for the production of the substances of general formula I according to the invention.

11. Uses of the compounds of general formula IVA or IVB



in which D stands for the group $-\text{NO}_2$, $-\text{NH}_2$ or $-\text{NH}(\text{CO})\text{OC}(\text{CH}_3)_3$, and K stands for C_1 - C_6 -alkyl or C_1 - C_6 -alkenyl that is optionally substituted with the group $-\text{NR}^3\text{R}^4$, and L stands for C_1 - C_6 -alkyl or C_1 - C_6 -alkenyl that is optionally substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkoxy, C_1 - C_6 -alkoxy- C_1 - C_6 -alkoxy or the group $-\text{NR}^3\text{R}^4$, and R^3 and R^4 have the meaning that is described in general formula I, as intermediate products for the production of substances of general formula I according to the invention.

12. Compounds of general formula V



in which Q, A, B and R¹ have the meaning that is described in general formula I, as intermediate products for the production of the substances of general formula I according to the invention, with the proviso that cyano-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid does not fall under general formula V.

13. Use of the compounds of general formula I, according to claims 1 to 5, for the production of a pharmaceutical agent for treating cancer, auto-immune diseases, chemotherapy agent-induced alopecia and mucositis, cardiovascular diseases, infectious diseases, nephrological diseases, chronic and acute neurodegenerative diseases and viral infections.

14. Use according to claim 13, characterized in that cancer is defined as solid tumors and leukemia; auto-immune diseases are defined as psoriasis, alopecia and multiple sclerosis; cardiovascular diseases are defined as stenoses, arterioscleroses and restenoses; infectious diseases are defined as diseases that are caused by unicellular parasites; nephrological diseases are defined as glomerulonephritis; chronic neurodegenerative diseases are defined as Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease; acute neurodegenerative diseases are defined as ischemias of the brain and neurotraumas; and viral infections are defined as cytomegalic infections, herpes, hepatitis B and C, and HIV diseases.

15. Pharmaceutical agents that contain at least one compound according to claims 1 to 5.

16. Pharmaceutical agents according to claim 15 for treating cancer, autoimmune diseases, cardiovascular diseases, infectious diseases, nephrological diseases, neurodegenerative diseases and viral infections.

17. Compounds according to claims 1 to 5 or pharmaceutical agents according to claim 15 or 16 with suitable formulation substances and vehicles.

18. Use of the compounds of general formula I, according to claims 1 to 5, and the pharmaceutical agents, according to claim 15 or 16, as inhibitors of the polo-like kinases.
19. Use according to claim 18, wherein the kinase is Plk1, Plk2, Plk3 or Plk4.
20. Use of the compounds of general formula I, according to claims 1 to 5, in the form of a pharmaceutical preparation for enteral, parenteral and oral administration.